P. Oztopcu-Vatan and M. Yildiz-Ozer / BIBAD, 12(1): 30-34, 2019

Keywords: BEAS-2B, ceranib-2, healthy cells, cytotoxicity, apoptosis


Previous studies demonstrated that ceranib-2 as a ceramidase inhibitor has potent cytotoxic activity and induces apoptosis in different cancer
cells. However, knowledge about the possible effects of ceranib-2 on healthy cells is limited. For this purpose, the morphological, cytotoxic
and apoptotic effects of ceranib-2 (1 to 100 μM) on human bronchial epithelial (BEAS-2B) cells were investigated. In the morphological
examination after ceranib-2 application for 24 and 48 h, the number of survived cells was decreased and apoptotic changes were observed due
to increase in concentration and treatment time. Ceranib-2 decreased cell viability and the IC50 values were determined as 48 and 4 μM for 24
and 48 h, respectively. C2-ceramide was also used as positive control and found less toxic with IC50 values of 57 and 43 μM for 24 and 48 h,
respectively. Moreover, we evaluated apoptotic/necrotic DNA fragmentation rates after 24 h application of ceranib-2 concentrations (10, 25 and
50 μM) and the apoptotic effect was higher than the necrotic effect compared to control by Cell Death Detection Elisa Plus Kit.
Consequently, we determined ceranib-2 had a more toxic effect on healthy human bronchial epithelial cells compared to ceramide analogues
and this effect increased due to time. The findings of our study indicated the importance of investigating potential anticancer agents on healthy